Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.6K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.6K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

805
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
805
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

25
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
25
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

923
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
923
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

662
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
662

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-Based Disparities in Health Care Access and Utilization Among Patients With Atrial Fibrillation.

JAMA network open·2026
Same author

PR Segment Depression - An Often Missed Clinically Important Electrocardiographic Finding.

The American journal of medicine·2026
Same author

Pretty Darned Good … But Not Quite Complete.

The American journal of cardiology·2026
Same author

Clinical trial report formats should be scientifically unadorned by irrelevance and be user oriented.

The American journal of medicine·2026
Same author

Patient health or corporate profits-Shouldn't the former come first?

The American journal of medicine·2026
Same author

The most bang for our buck?

The American journal of medicine·2026

Related Experiment Video

Updated: Aug 10, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.7K

Perspective on Antiarrhythmic Drug Combinations.

James A Reiffel1, Victoria M Robinson2, Peter R Kowey3

  • 1Vagelos College of Physicians & Surgeons, Columbia University, New York City, New York.

The American Journal of Cardiology
|February 14, 2023
PubMed
Summary
This summary is machine-generated.

Combining antiarrhythmic drugs (AADs) may improve treatment efficacy and safety for arrhythmias like ventricular tachycardia and atrial fibrillation. This review explores the rationale, considerations, and existing literature for AAD combinations.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.1K

Related Experiment Videos

Last Updated: Aug 10, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.7K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.1K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Combination drug therapy is standard for many cardiovascular conditions.
  • The use of combined antiarrhythmic drugs (AADs) is infrequently discussed.
  • Potential benefits include enhanced efficacy, improved tolerance, and increased safety through additive or complementary mechanisms.

Purpose of the Study:

  • To review the potential for using combinations of antiarrhythmic drugs (AADs).
  • To cover the rationale, considerations, and supporting literature for AAD combinations.
  • To address both ventricular arrhythmias and atrial fibrillation.

Main Methods:

  • Literature review of published studies on antiarrhythmic drug combinations.
  • Analysis of the rationale for combining AADs based on pharmacological mechanisms.
  • Discussion of clinical considerations for implementing AAD combinations.

Main Results:

  • While specific combination studies are scarce, theoretical benefits exist.
  • Mechanisms for improved efficacy and safety through drug combinations are plausible.
  • Existing data, though limited, provides a foundation for further investigation.

Conclusions:

  • Combination therapy with AADs presents a potential strategy for managing arrhythmias.
  • Further research is warranted to explore the efficacy and safety of specific AAD combinations.
  • This approach could offer new therapeutic options for ventricular arrhythmias and atrial fibrillation.